The Institute for Clinical and Economic Review (ICER) says Spark Therapeutics' recently approved gene therapy Luxturna in most cases should cost about 75 percent less than the proposed price, as reported by Business Insider.
Spark has indicated that the one-time treatment would carry a list price of $850 000, or $425 000 per eye, for a form of blindness that affects only 1000 to 2000 patients in the US.
ICER chief medical officer David Rhind remarked "we believe it's a scientific milestone, but that for the majority of patients being treated, the cost is not in line with what's considered cost effective."
Spark is in the process of negotiating payments and reimbursement with the government and private health insurers ahead of a planned March launch of the therapy, the news source said.
To read more NewsPoints articles, click here.